Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D1295 | Amoxicillin

Molecular Formula C16H19N3O5S
Molecular Weight 365.4
Structure
State solid
Route of elimination Most of the amoxicillin is excreted unchanged in the urine; its excretion can be delayed by concurrent administration of probenecid.
Protein binding In blood serum, amoxicillin is approximately 20% protein-bound
Half life 61.3 minutes
Absorption Rapidly absorbed after oral administration.
Description Antibiotic

J

A

J01CR50 Combinations of penicillins


[J01CR] Combinations of penicillins, incl. beta-lactamase inhibitors


[J01C] BETA-LACTAM ANTIBACTERIALS, PENICILLINS


[J01] ANTIBACTERIALS FOR SYSTEMIC USE


[J] Antiinfectives for systemic use

J01CA04 Amoxicillin


[J01CA] Penicillins with extended spectrum


[J01C] BETA-LACTAM ANTIBACTERIALS, PENICILLINS


[J01] ANTIBACTERIALS FOR SYSTEMIC USE


[J] Antiinfectives for systemic use

A02BD15 Vonoprazan, amoxicillin and metronidazole


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD14 Vonoprazan, amoxicillin and clarithromycin


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD13 Rabeprazole, amoxicillin and metronidazole


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD12 Rabeprazole, amoxicillin and clarithromycin


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD11 Pantoprazole, amoxicillin, clarithromycin and metronidazole


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD10 Lansoprazole, amoxicillin and levofloxacin


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD07 Lansoprazole, amoxicillin and clarithromycin


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD06 Esomeprazole, amoxicillin and clarithromycin


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD05 Omeprazole, amoxicillin and clarithromycin


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD04 Pantoprazole, amoxicillin and clarithromycin


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD03 Lansoprazole, amoxicillin and metronidazole


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

A02BD01 Omeprazole, amoxicillin and metronidazole


[A02BD] Combinations for eradication of Helicobacter pylori


[A02B] DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)


[A02] DRUGS FOR ACID RELATED DISORDERS


[A] Alimentary tract and metabolism

Toxicity Dose Time Species Model Method Action Positive criterion Reference
MEMBRANE POTENTIAL > 400 µM 30 mins mouse liver mitochondria Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) decrease EC20 36
RESPIRATION 90.8 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. increase EC20 36
RESPIRATION 188.8 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. increase EC20 36
SWELLING > 400 µM 30 mins mouse liver mitochondria swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) increase EC20 36

Target Dose Time Species Model Method Action Positive criterion Reference
Cytochrome c > 400 µM 30 mins mouse liver mitochondria Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) release EC20 36

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 56 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]


H334 (98.21%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P261, P272, P280, P285, P302+P352, P304+P341, P321, P333+P313, P342+P311, P363, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
Danger

H317: May cause an allergic skin reaction [Warning Sensitization, Skin]


H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]


 P261, P272, P280, P285, P302+P352, P304+P341, P321, P333+P313, P342+P311, P363, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
rat LD50 oral > 15gm/kg (15000mg/kg) Drugs in Japan Vol. 6, Pg. 38, 1982.
mouse LD50 intraperitoneal 3590mg/kg (3590mg/kg) Drugs in Japan Vol. -, Pg. 59, 1990.
man TDLo oral 40mg/kg/4D (40mg/kg) Lancet. Vol. 2, Pg. 707, 1978.
rat LD50 intraperitoneal 2870mg/kg (2870mg/kg) Drugs in Japan Vol. -, Pg. 59, 1990.
child TDLo oral 682mg/kg (682mg/kg) Clinical Pediatrics Vol. 32, Pg. 735, 1993.
rat LD50 subcutaneous > 8gm/kg (8000mg/kg) Drugs in Japan Vol. -, Pg. 59, 1990.
mouse LD50 intracrebral > 500mg/kg (500mg/kg) brain and coverings: recordings from specific areas of cns Chemotherapy Vol. 26, Pg. 196, 1980.
mouse LD50 subcutaneous > 20mg/kg (20mg/kg) Drugs in Japan Vol. -, Pg. 59, 1990.
mouse LD50 oral > 25gm/kg (25000mg/kg) Drugs in Japan Vol. 6, Pg. 38, 1982.
man TDLo oral 7143ug/kg (7.143mg/kg) skin and appendages (skin): "dermatitis, other: after systemic exposure" Allergy. Vol. 52(Suppl,
child TDLo oral 300mg/kg (300mg/kg) Clinical Pediatrics Vol. 32, Pg. 735, 1993.


  • DrugBank DB01060
    CAS Number 26787-78-0, 61336-70-7, 88105-29-7
    PubChem Compound 33613